Longevity & AgingSenolytic Vaccine Plus Stem Cells Outperforms Either Alone in Mouse Study
Researchers tested whether clearing senescent cells first could help stem cell therapies work better. Senescent cells release inflammatory molecules (SASP) that suppress stem cell activity. The study combined a senolytic vaccine called SenoVax with mesenchymal stem cells in two mouse injury models — one using a liver toxin, one using a chemotherapy drug. In both models, the combination reduced inflammatory markers more than either treatment alone and raised markers linked to tissue repair. Physical performance also improved. The results suggest that removing the hostile senescent-cell environment may unlock stem cell potential. However, these are acute injury models in mice, not natural aging, and the company behind SenoVax funded the research, raising questions about independent replication before any clinical excitement is warranted.
